Updates on use of Tixagevimab-Cilgavimab (Evusheld)

The following updates have been approved by the Pharmacy & Therapeutics Committee effective June 21, 2022, for the use of Tixagevimab-Cilgavimab (Evusheld) in adult and pediatric patients. Interim Guidance for the Use of Tixagevimab-Cilgavimab (Evusheld) in Adult Patients Interim Guidance for the Use of Tixagevimab Cilgavimab (Evusheld) in Pediatric Patients If you have questions, please… Read More

Updated pharmacotherapy guidance for adult and pediatric patients

The UK HealthCare Pharmacy & Therapeutics Committee has approved the following updates and additions to interim guidance for adult and pediatric patients. New guidelines Interim Guidance for the Use of Tixagevimab-Cilgavimab (Evusheld) in Adult Patients (4-19-22) Interim Guidance for the Use of Tixagevimab-Cilgavimab (Evusheld) in Pediatric Patients (4-22-22) Interim Pharmacotherapy Guidance for SARS-CoV-2 (COVID-19) Infection… Read More